Skip to main content

Advertisement

Table 2 Univariate analysis for factors associated with response rate, progression free survival and overall survival in 355 cervical cancer patients

From: Neutrophil-lymphocyte ratio as a predictor of oncologic outcomes in stage IVB, persistent, or recurrent cervical cancer patients treated by chemotherapy

Variables Overall response rate Progression free survival Overall survival
n (%) P HR (95% CI) P HR (95% CI) P
Age, years
 < 50 (n = 157) 66 (42.0) 0.113 reference   reference  
 ≥ 50 (n = 198) 67 (33.8)   1.091 (0.875–1.362) 0.439 1.050 (0.722–1.527) 0.797
Menopausal status
 Premenopause (n = 186) 71 (38.2) 0.773 reference   reference  
 Postmenopause (n = 169) 62 (36.7)   1.012 (0.812–1.260) 0.917 1.002 (0.691–1.452) 0.994
Body mass index, kg/m2
 < 18.5 (n = 192) 61 (31.8) 0.003a 1.659 (1.160–2.372) 0.003 1.598 (1.035–2.466) 0.034
 18.5–24.9 (n = 50) 15 (30.0)   1.463 (1.139–1.879) 0.003 2.571 (1.441–4.587) 0.001
 ≥ 25 (n = 113) 57 (50.4)   reference   reference  
Patient group
 Primary (n = 63) 22 (34.9) 0.646 reference   reference  
 Persistent/recurrent (n = 292) 111 (38.0)   0.772 (0.582–1.025) 0.073 0.707 (0.436–1.149) 0.162
Initial FIGO stages (n = 351)
 I-II (n = 164) 66 (40.2) 0.395 reference   reference  
 III-IV (n = 187) 67 (35.8)   1.294 (1.037–1.617) 0.023 0.915 (0.629–1.329) 0.640
Histopathology
 Non-SCC (n = 146) 60 (41.1) 0.237 reference   reference  
 SCC (n = 209) 73 (34.9)   1.281 (1.023–1.604) 0.031 1.350 (0.920–1.980) 0.125
Disease site before chemotherapy initiation
 Locoregional (n = 138) 56 (40.6) 0.334 reference   reference  
 Distant metastasis (n = 217) 77 (35.5)   1.353 (1.076–1.702) 0.010 1.971 (1.302–2.983) 0.001
White blood cell count, /mm3
 ≤ 10,000 (n = 300) 118 (39.3) 0.089 reference   reference  
 > 10,000 (n = 55) 15 (27.3)   1.683 (1.252–2.263) 0.001 2.339 (1.487–3.678) < 0.001
Neutrophil count, /mm3
 ≤ 7000 (n = 288) 114 (39.6) 0.087 reference   reference  
 > 7000 (n = 67) 19 (28.4)   1.673 (1.268–2.208) < 0.001 2.610 (1.706–3.993) < 0.001
Lymphocyte count, /mm3
 ≥ 2000 (n = 44) 20 (45.5) 0.242 reference   reference  
 < 2000 (n = 311) 113 (36.3)   1.353 (0.960–1.908) 0.085 1.545 (0.880–2.713) 0.130
NLR
 < 3.6 (n = 174) 77 (44.3) 0.010b reference   reference  
 ≥ 3.6 (n = 181) 56 (30.9)   1.648 (1.318–2.060) < 0.001 2.759 (1.873–4.065) < 0.001
Monocyte count, /mm3
 ≤ 970 (n = 348) 132 (37.9) 0.263 reference   reference  
 > 970 (n = 7) 1 (14.3)   3.038 (1.428–6.462) 0.004 3.641 (0.884–14.994) 0.074
Eosinophil count, /mm3
 ≤ 750 (n = 340) 126 (37.1) 0.452 reference   reference  
 > 750 (n = 15) 7 (46.7)   1.207 (0.706–2.064) 0.491 0.679 (0.215–2.138) 0.508
Hemoglobin, g/dL
 ≥ 12 (n = 93) 44 (47.3) 0.022c reference   reference  
 < 12 (n = 262) 89 (34.0)   1.260 (0.982–1.618) 0.069 1.308 (0.853–2.007) 0.219
Platelet count, /mm3
 ≤ 400,000 (n = 246) 95 (38.6) 0.500 reference   reference  
 > 400,000 (n = 109) 38 (37.5)   1.560 (1.232–1.975) < 0.001 1.963 (1.327–2.903) 0.001
  1. HR hazard ratio, CI confidence interval, FIGO the International Federation of Gynecology and Obstetrics, NLR neutrophil-lymphocyte ratio, SCC squamous cell carcinoma
  2. aStatistical significance was observed between patients with BMI ≥25 kg/m2and BMI 18.5–24.9 kg/m2, and between patients with BMI ≥25 kg/m2 and BMI < 18.5 kg/m2
  3. bOdds ratio = 1.772, 95% CI: 1.147–2.736
  4. cOdds ratio = 1.745, 95% CI: 1.079–2.823